Cargando…

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19

The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. However, the mutated clone composition may impact the probability of response...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristiano, Antonio, Palmieri, Raffaele, Fabiani, Emiliano, Ottone, Tiziana, Divona, Mariadomenica, Savi, Arianna, Buccisano, Francesco, Maurillo, Luca, Tarella, Corrado, Arcese, William, Voso, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083951/
https://www.ncbi.nlm.nih.gov/pubmed/35615323
http://dx.doi.org/10.4084/MJHID.2022.041